Total Payments
$26,526
2024 Payments
$1,641
Companies
73
Transactions
789
Medicare Patients
11,170
Medicare Billing
$3.2M
Payment Breakdown by Category
Food & Beverage$16,153 (60.9%)
Consulting$7,820 (29.5%)
Gifts$2,159 (8.1%)
Education$378.30 (1.4%)
Travel$16.10 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $16,153 | 747 | 60.9% |
| Consulting Fee | $7,820 | 2 | 29.5% |
| Gift | $2,159 | 16 | 8.1% |
| Education | $378.30 | 23 | 1.4% |
| Travel and Lodging | $16.10 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| INSYS Therapeutics Inc | $5,854 | 9 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $3,451 | 101 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,378 | 35 | $0 (2024) |
| Genentech USA, Inc. | $1,889 | 79 | $0 (2024) |
| Amgen Inc. | $1,090 | 42 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,050 | 69 | $0 (2024) |
| PFIZER INC. | $838.37 | 69 | $0 (2024) |
| TESARO, Inc. | $632.74 | 16 | $0 (2019) |
| Daiichi Sankyo Inc. | $515.13 | 9 | $0 (2024) |
| Janssen Biotech, Inc. | $488.94 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,641 | 69 | PFIZER INC. ($142.36) |
| 2023 | $867.40 | 37 | Mirati Therapeutics, Inc. ($121.86) |
| 2022 | $613.62 | 13 | Adaptive Biotechnologies Corporation ($148.19) |
| 2021 | $1,047 | 11 | Daiichi Sankyo Inc. ($360.04) |
| 2019 | $5,216 | 94 | AstraZeneca Pharmaceuticals LP ($2,596) |
| 2018 | $6,570 | 286 | Novartis Pharmaceuticals Corporation ($1,786) |
| 2017 | $10,571 | 279 | INSYS Therapeutics Inc ($5,813) |
All Payment Transactions
789 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $24.17 | General |
| Category: Oncology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $22.88 | General |
| Category: Cardiovascular | ||||||
| 12/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $27.29 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $23.11 | General |
| Category: Hematology/Oncology | ||||||
| 12/03/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $22.70 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $25.22 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $34.35 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $19.16 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $26.24 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: Rare Disease | ||||||
| 11/04/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: Oncology | ||||||
| 10/31/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $25.42 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.69 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.24 | General |
| Category: Hematology | ||||||
| 10/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $27.79 | General |
| Category: Oncology | ||||||
| 10/10/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $34.65 | General |
| Category: Oncology | ||||||
| 10/08/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.61 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.85 | General |
| 09/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.81 | General |
| 09/20/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $24.47 | General |
| Category: Hematology | ||||||
| 09/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 58 | 2,944 | 35,642 | $4.8M | $989,208 |
| 2022 | 63 | 3,065 | 49,121 | $4.4M | $867,476 |
| 2021 | 58 | 2,714 | 45,997 | $3.7M | $838,882 |
| 2020 | 53 | 2,447 | 36,232 | $2.9M | $534,670 |
Total Patients
11,170
Total Services
166,992
Medicare Billing
$3.2M
Procedure Codes
232
All Medicare Procedures & Services
232 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 17 | 9,600 | $1.3M | $416,679 | 31.6% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 14 | 3,600 | $842,568 | $118,378 | 14.0% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 71 | 84 | $403,368 | $97,270 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 210 | 643 | $236,624 | $59,234 | 25.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 2,280 | $151,800 | $42,631 | 28.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 111 | 237 | $117,552 | $32,257 | 27.4% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 12 | 300 | $404,400 | $27,053 | 6.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 84 | 254 | $179,578 | $25,946 | 14.4% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2023 | 23 | 80 | $220,960 | $22,775 | 10.3% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 11 | 13 | $64,077 | $15,028 | 23.5% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 19 | 34 | $58,548 | $11,307 | 19.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 263 | 1,079 | $69,056 | $11,151 | 16.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 260 | 1,072 | $38,592 | $8,146 | 21.1% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 74 | 86 | $56,502 | $7,809 | 13.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 46 | 46 | $32,614 | $7,312 | 22.4% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 45 | 49 | $52,283 | $7,232 | 13.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 40 | 110 | $27,170 | $6,753 | 24.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 57 | 130 | $40,690 | $6,327 | 15.5% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 259 | 1,036 | $32,116 | $6,124 | 19.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 67 | 250 | $39,250 | $5,640 | 14.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 202 | 624 | $12,480 | $5,242 | 42.0% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 90 | 247 | $24,453 | $4,589 | 18.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 32 | 90 | $30,960 | $4,555 | 14.7% |
| G6013 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | Office | 2023 | 11 | 24 | $16,800 | $4,474 | 26.6% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 46 | 119 | $17,017 | $4,169 | 24.5% |
About Dr. Barry Firstenberg, DO
Dr. Barry Firstenberg, DO is a Hematology & Oncology healthcare provider based in Grapevine, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1215939764.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Barry Firstenberg, DO has received a total of $26,526 in payments from pharmaceutical and medical device companies, with $1,641 received in 2024. These payments were reported across 789 transactions from 73 companies. The most common payment nature is "Food and Beverage" ($16,153).
As a Medicare-enrolled provider, Firstenberg has provided services to 11,170 Medicare beneficiaries, totaling 166,992 services with total Medicare billing of $3.2M. Data is available for 4 years (2020–2023), covering 232 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Grapevine, TX
- Active Since 08/15/2005
- Last Updated 11/16/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1215939764
Products in Payments
- SYNDROS (Drug) $5,821
- IMFINZI (Drug) $2,492
- KISQALI (Drug) $2,287
- OPDIVO (Biological) $670.87
- Avastin (Biological) $652.35
- ZEJULA (Drug) $632.74
- Kyprolis (Biological) $595.31
- Enhertu (Drug) $485.42
- TECENTRIQ (Biological) $378.42
- KEYTRUDA (Biological) $371.64
- NERLYNX (Drug) $356.62
- AFINITOR (Drug) $356.05
- LYNPARZA (Drug) $346.83
- DARZALEX (Biological) $329.22
- Cabometyx (Drug) $309.40
- JAKAFI (Drug) $297.00
- GILOTRIF (Drug) $268.24
- IBRANCE (Drug) $259.01
- Perjeta (Biological) $256.37
- GAZYVA (Biological) $241.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.